Supernus Pharmaceuticals annual asset turnover
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Asset Turnover Growth & History (SUPN)
Supernus Pharmaceuticals's asset turnover was 0.51 for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.51 | 0.01 | +1.89% |
| 2024 | 2024-12-31 | 0.50 | 0.09 | +22.71% |
| 2023 | 2023-12-31 | 0.41 | 0.01 | +3.62% |
| 2022 | 2022-12-31 | 0.39 | 0.03 | +8.35% |
| 2021 | 2021-12-31 | 0.36 | −0.03 | −7.04% |
| 2020 | 2020-12-31 | 0.39 | 0.02 | +6.33% |
| 2019 | 2019-12-31 | 0.37 | −0.22 | −37.00% |
| 2018 | 2018-12-31 | 0.58 | −0.24 | −29.18% |
| 2017 | 2017-12-31 | 0.82 | −0.04 | −4.59% |
| 2016 | 2016-12-31 | 0.86 | −0.04 | −4.77% |
| 2015 | 2015-12-31 | 0.91 | 0.16 | +21.16% |
| 2014 | 2014-12-31 | 0.75 | 0.63 | +537.92% |
| 2013 | 2013-12-31 | 0.12 | 0.10 | +485.23% |
| 2012 | 2012-12-31 | 0.02 | — | — |
Supernus Pharmaceuticals quarterly asset turnover
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.59 | 0.10 | +19.87% |
| Q1 2026 | 2026-03-31 | 0.55 | 0.04 | +8.26% |
| Q4 2025 | 2025-12-31 | 0.51 | 0.01 | +1.89% |
| Q3 2025 | 2025-09-30 | 0.49 | −0.00 | −0.56% |
| Q2 2025 | 2025-06-30 | 0.49 | 0.01 | +2.05% |
| Q1 2025 | 2025-03-31 | 0.50 | 0.12 | +30.56% |
| Q4 2024 | 2024-12-31 | 0.50 | 0.09 | +22.71% |
| Q3 2024 | 2024-09-30 | 0.50 | 0.09 | +21.03% |
| Q2 2024 | 2024-06-30 | 0.48 | 0.06 | +13.84% |
| Q1 2024 | 2024-03-31 | 0.39 | −0.00 | −0.95% |
| Q4 2023 | 2023-12-31 | 0.41 | 0.01 | +3.62% |
| Q3 2023 | 2023-09-30 | 0.41 | 0.00 | +1.05% |
| Q2 2023 | 2023-06-30 | 0.42 | 0.04 | +10.05% |
| Q1 2023 | 2023-03-31 | 0.39 | 0.01 | +1.95% |
| Q4 2022 | 2022-12-31 | 0.39 | 0.03 | +8.35% |
| Q3 2022 | 2022-09-30 | 0.41 | 0.04 | +10.20% |
| Q2 2022 | 2022-06-30 | 0.39 | 0.01 | +3.47% |
| Q1 2022 | 2022-03-31 | 0.38 | −0.03 | −7.36% |
| Q4 2021 | 2021-12-31 | 0.36 | −0.03 | −7.04% |
| Q3 2021 | 2021-09-30 | 0.37 | 0.00 | +0.94% |
| Q2 2021 | 2021-06-30 | 0.37 | 0.04 | +12.20% |
| Q1 2021 | 2021-03-31 | 0.41 | 0.05 | +13.59% |
| Q4 2020 | 2020-12-31 | 0.39 | 0.02 | +6.33% |
| Q3 2020 | 2020-09-30 | 0.36 | −0.04 | −9.33% |
| Q2 2020 | 2020-06-30 | 0.33 | −0.09 | −22.20% |
| Q1 2020 | 2020-03-31 | 0.36 | −0.07 | −16.81% |
| Q4 2019 | 2019-12-31 | 0.37 | −0.22 | −37.00% |
| Q3 2019 | 2019-09-30 | 0.40 | −0.18 | −31.01% |
| Q2 2019 | 2019-06-30 | 0.43 | −0.17 | −28.66% |
| Q1 2019 | 2019-03-31 | 0.44 | −0.15 | −25.26% |
| Q4 2018 | 2018-12-31 | 0.58 | −0.24 | −29.18% |
| Q3 2018 | 2018-09-30 | 0.58 | −0.24 | −29.20% |
| Q2 2018 | 2018-06-30 | 0.60 | −0.30 | −33.07% |
| Q1 2018 | 2018-03-31 | 0.58 | −0.30 | −33.93% |
| Q4 2017 | 2017-12-31 | 0.82 | −0.04 | −4.59% |
| Q3 2017 | 2017-09-30 | 0.82 | −0.05 | −5.23% |
| Q2 2017 | 2017-06-30 | 0.89 | −0.07 | −6.82% |
| Q1 2017 | 2017-03-31 | 0.88 | −0.09 | −9.36% |
| Q4 2016 | 2016-12-31 | 0.86 | −0.04 | −4.77% |
| Q3 2016 | 2016-09-30 | 0.87 | −0.05 | −5.70% |
| Q2 2016 | 2016-06-30 | 0.96 | 0.01 | +0.70% |
| Q1 2016 | 2016-03-31 | 0.98 | 0.03 | +2.95% |
| Q4 2015 | 2015-12-31 | 0.91 | 0.16 | +21.16% |
| Q3 2015 | 2015-09-30 | 0.92 | 0.37 | +65.84% |
| Q2 2015 | 2015-06-30 | 0.95 | 0.37 | +63.96% |
| Q1 2015 | 2015-03-31 | 0.95 | 0.73 | +332.93% |
| Q4 2014 | 2014-12-31 | 0.75 | 0.61 | +453.97% |
| Q3 2014 | 2014-09-30 | 0.56 | — | — |
| Q2 2014 | 2014-06-30 | 0.58 | 0.57 | +3727.81% |
| Q1 2014 | 2014-03-31 | 0.22 | 0.20 | +842.69% |
| Q4 2013 | 2013-12-31 | 0.14 | 0.12 | +573.91% |
| Q2 2013 | 2013-06-30 | 0.02 | — | — |
| Q1 2013 | 2013-03-31 | 0.02 | — | — |
| Q4 2012 | 2012-12-31 | 0.02 | — | — |
Supernus Pharmaceuticals asset turnover trends
Over the last five fiscal years, Supernus Pharmaceuticals's asset turnover increased from 0.39 to 0.51, a change of 0.12. The latest reported quarter, Q2 2026, shows 0.59.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
